INS and type 2 diabetes mellitus: Of note, a GalNAc-conjugated oligonucleotide targeting miR-103/-107 (RG-125, AZD4076) has entered phase I/IIa randomized, single-blind, placebo-controlled clinical trial (NCT02826525) investigating the safety and tolerability of AZD4076 and assessing its effect on insulin sensitivity and liver fat content in patients with T2DM and non-alcoholic fatty liver disease, although there are still no results in the available literature.